Multiple treatment transitions in patients with NMOSD are associated with increased neurological harm, including increased relapse risk and disease progression.
The use of the monoclonal antibody satralizumab for the long-term treatment of neuromyelitis optica spectrum disorder provides sustained freedom from relapse with no new safety concerns over 5 years.
The federal agency warned on Tuesday that it has received reports of people experiencing "adverse events" after using compounded versions of the drugs.